Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study

Despite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating diso...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC psychiatry 2024-11, Vol.24 (1), p.779-11, Article 779
Hauptverfasser:	Said, Olena, Stringer, Dominic, Sengun Filiz, Ece, Mutwalli, Hiba, Bektas, Sevgi, Akkese, Melahat Nur, Kellermann, Vanessa, Ireland, Katie, Tyrrell-Bunge, Elizabeth, Beishon-Murley, Demelza, Khor, Joel W T, Allman, Lee, Barker, Joanna, Kotze, Nicus, Carter, Ben, Simic, Mima, Sually, Dilveer Singh, Bentley, Jessica, Young, Allan H, Madden, Sloane, Byford, Sarah, Landau, Sabine, Lawrence, Vanessa, Treasure, Janet, Schmidt, Ulrike, Nicholls, Dasha, Himmerich, Hubertus
Format:	Artikel
Sprache:	eng
Schlagworte:	Adherence Adolescent Analysis Anorexia Anorexia nervosa Anorexia Nervosa - drug therapy Antipsychotic Agents - therapeutic use Antipsychotics Attrition Body Mass Index Body size Child COVID-19 Diagnosis Dosage and administration Drug therapy Eating disorders Feasibility Feasibility Studies Female Health aspects Humans Male Olanzapine Olanzapine - therapeutic use Patients Pediatrics Psychological aspects Psychology, Pathological Psychopathology Psychotropic drugs Recruitment Remission Social aspects Teenagers Treatment Outcome Young Adult Youth
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Despite the availability of evidence-based treatments for anorexia nervosa (AN), remission rates are moderate, and mortality is high. Olanzapine is used as adjunct therapy for AN in case of insufficient response to first-line treatments, even though the evidence is limited. Its effect on eating disorder (ED) psychopathology, its efficacy and tolerability, and its acceptability and adherence rate are unclear. We assessed the feasibility of a future definitive trial on olanzapine in young people with AN in an open-label, one-armed feasibility study that aimed to include 55 patients with AN or atypical AN aged 12-24 who gained
ISSN:	1471-244X 1471-244X
DOI:	10.1186/s12888-024-06215-y